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Abstract
Background: Monitoring of serum lipid concentrations at the population level is an important public health tool to
describe progress in cardiovascular disease risk control and prevention. Using data from two nationally representative
health surveys of adults 18–79 years, this study identified changes in mean serum total cholesterol (TC), high-density
lipoprotein cholesterol (HDL-C), and triglycerides (TG) in relation to changes in potential determinants of serum lipids
between 1997–99 and 2008–11 in Germany.
Methods: Sex-specific multivariable linear regression analyses were performed with serum lipids as dependent variables
and survey wave as independent variable and adjusted for the following covariables: age, fasting duration, educational
status, lifestyle, and use of medication.
Results: Mean TC declined between the two survey periods by 13 % (5.97 mmol/l vs. 5.19 mmol/l) among men and by
12 % (6.03 mmol/l vs. 5.30 mmol/l) among women. Geometric mean TG decreased by 14 % (1.66 mmol/l vs. 1.42 mmol/l)
among men and by 8 % (1.20 mmol/l vs. 1.10 mmol/l) among women. Mean HDL-C remained unchanged among men
(1.29 mmol/l vs. 1.27 mmol/l), but decreased by 5 % among women (1.66 mmol/l vs. 1.58 mmol/l). Sports activity and
coffee consumption increased, while smoking and high alcohol consumption decreased only in men. Processed
food consumption increased and wholegrain bread consumption decreased in both sexes, and obesity increased
among men. The use of lipid-lowering medication, in particular statins nearly doubled over time in both sexes.
Among women, hormonal contraceptive use increased and postmenopausal hormone therapy halved over time.
The changes in lipid levels between surveys remained significant after adjusting for covariables.
Conclusion: Serum TC and TG considerably declined over one decade in Germany, which can be partly explained by
increased use of lipid-lowering medication and improved lifestyle among men. The decline in serum lipids among
women, however, remains unexplained.
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Background
Increased low density lipoprotein-cholesterol (LDL-C)
and total cholesterol (TC) serum concentrations are
among the major modifiable risk factors of cardiovascular
disease (CVD) amenable to life style and pharmaceutical
intervention [1]. Other dyslipidaemias, including low high
density lipoprotein cholesterol (HDL-C) and elevated
triglyceride (TG) levels are markers of increased CVD risk;
however, the evidence for a causal relationship and
practical implications for treatment are less clear [2, 3].
Monitoring of serum lipid concentrations and other
major CVD risk factors at the population level is an
important public health tool to describe progress in
CVD risk control and prevention. Analyses conducted
by the Global Burden of Metabolic Risk Factors of
Chronic Diseases Collaborating Group showed that
mean serum cholesterol declined by 0.2 mmol/l per
decade for men and women in high-income regions
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between 1990 and 2008 [4]. Serum lipid levels are de-
termined by genetic [5] as well as acquired factors, such
as lifestyle [6], in particular diet, physical activity, and
smoking, use of lipid-lowering medications, use of
other medications e.g. hormonal contraceptives [7] and
postmenopausal hormone therapy [8], and diseases [9].
Trends in serum lipids and their underlying determi-
nants are likely to differ between populations due to
country-specific trends in lifestyle and medication use;
hence country-specific data are needed for public health
recommendations and health policy consulting. Significant
declines in serum lipids at the population level have been
reported from the United States (US) [10] and several
European countries [11–13]. Previous analyses in Germany
were limited to the population of Western Germany and
the time period between 1984 and 1998 [14] and need an
update. Based on data from two nationally representative
health interview and examination surveys conducted in
1997–99 and in 2008–11, we examined changes in serum
TC, TG, and HDL-C among 18–79-year old adults in
Germany between the two survey periods in relation to
changes in lifestyle and use of lipid-lowering medication.
Methods
Study design
Data from the German National Health Interview and
Examination Survey 1997–99 (GNHIES98) and the sub-
sequent German Health Interview and Examination Sur-
vey for Adults 2008–11 (DEGS1) were used. The design
and study protocol of both surveys has been previously
described in detail [15, 16]. In brief, in both surveys par-
ticipants were selected using a two-stage clustered sam-
pling procedure. Within the community, which was the
primary sampling unit, individuals are sampled randomly
from local population registries. GNHIES98 was approved
by the Board of the Federal Commissioner for Data Pro-
tection Berlin and DEGS1 was approved by the Federal
and State Commissioners for Data Protection and the
Charité - Universitätsmedizin Berlin ethics committee
(No. EA2/047/08). The implementation of the study con-
forms to the principles of the Helsinki Declaration. In-
formed consent was obtained from all participants
prior to inclusion in the study. GNHIES98 comprises
7124 participants and DEGS1 comprises 7115 partici-
pants at the age of 18–79 years, who had participated
in the examination part.
Laboratory analyses
In both surveys, venous blood samples were taken at the
study centres. For logistic reasons and in order to enhance
participation, appointments were scheduled throughout
the day at the participants’ convenience. The time of the
blood sampling as well as the number of hours since last
meal were recorded. Fasting duration was higher in the
2008–11 survey compared to the 1997–99 survey due to a
change in the instructions provided in the invitation letter.
In the 1997–99 survey blood was drawn in a non-fasting
state. In the 2008–11 survey, participants, except those
with diagnosed diabetes, were encouraged to schedule
morning appointments after an overnight fasting period of
at least eight hours; for appointments later during the day,
a fasting period of at least four hours was recommended.
Blood samples were processed within one hour and stored
at −40 °C until analysis in the central laboratory unit at
the Robert Koch Institute. Serum lipid levels were deter-
mined by an enzymatic procedure, based on the CHOD-
PAP method (TC, HDL-C) and the GPO-PAP method
(TG). While the principle of measurement remained the
same, the analytic system for serum lipids changed dur-
ing the study period (GNHIES98: MEGA, Merck,
Germany; DEGS1: Architect ci2800, Abbott, Germany).
All processes of laboratory analyses were performed in
accordance with standard operating procedures.
Covariables
Information on lifestyle was assessed using a self-
administered questionnaire. Smoking was assessed using
five categories in GNHIES98 (“yes, daily”, “yes, occa-
sionally”, “ex-smoker, less than 12 month”, “ex-smoker,
more than 1 year”, “never”) and four categories in
DEGS1 (“yes, daily”, “yes, occasionally”, “ex-smoker”,
“never”). For the present analyses, current smoking was
categorized as “no”, “occasionally”, and “daily”. Sports
activity was assessed by five categories (“no”, “less than
1 h”, “regularly 1–2 h”, ”regularly 2-4 h”, “regularly
more than 4 h”) in both surveys and re-categorised to
“no”, “up to 2 h per week”, and “regularly, at least 2 h
per week”.
In GNHIES98, a self-administered questionnaire in-
cluded questions on the frequency of food and non-
alcoholic beverage consumption during the last 12 months.
In addition the usual amounts of alcoholic drinks per
occasion were asked. In DEGS1 a semi-quantitative self-
administered food frequency questionnaire was used to
assess frequency and portion size of food and beverage
consumption (during the last 4 weeks). Dietary compo-
nents that influence serum lipid levels are mainly satu-
rated fatty acids, polyunsaturated fatty acids, trans fatty
acids (TFA), cholesterol and fibre [17]. Due to limited in-
formation on food intake, the ratio of polyunsaturated to
saturated fatty acids or even changes in white to red meat
consumption could not be taken into account. Based on
the data available, we included consumption of wholegrain
bread [18], processed foods [19], coffee [20] and alcohol
[21] in our models, which were significantly associated
with serum lipid levels in previous studies. Detailed infor-
mation on the categorization of dietary variables is shown
in Additional file 1: Table S1. High alcohol consumption
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was defined as more than 20 g per day for men and more
than 10 g for women [22].
Anthropometric measurements were performed in light
clothing without shoes in GNHIES98 and in underwear
without shoes in DEGS1. Body height was measured with
a precision of 0.1 cm and body weight was measured with
a precision of 0.1 kg. Body mass index (BMI) was calcu-
lated as body weight (kg) divided by height squared (m2)
and categorized as normal weight (BMI < 25 kg/m2), over-
weight (25 kg/m2 ≤ BMI < 30 kg/m2), and obese (BMI >
30 kg/m2) according to WHO recommendations [23].
Any medication taken within seven days prior to the
interview was recorded and validated based on the ori-
ginal containers brought to the study centre [24]. Classifi-
cation was based on the most currently available version
of the Anatomical Therapeutic Chemical (ATC) classifica-
tion system. We considered the following medications
known to affect blood lipids: lipid-lowering medications
(C10) especially statins (C10AA, C10BA), hormonal
contraceptives (G02B, G03A, G03HB01, G03FB03), and
postmenopausal hormone therapy (G03C, G03D, G03F
excluding G03FB03, G03HB).
The educational status was assessed using a self-
administered questionnaire and categorized as “low”,
“middle”, and “high” according to Comparative Analysis
of Social Mobility in Industrial Nations (CASMIN) clas-
sification system [25].
Analysis
Participants with missing values on serum lipid levels,
lifestyle and use of medication were excluded, resulting
in a final study sample of 6432 subjects in GNHIES98
(3144 men, 3288 women) and 6604 subjects in DEGS1
(3146 men, 3458 women). All analyses were stratified for
sex. Survey-specific means, percentages and 95 % confi-
dence intervals were calculated. Differences between
survey-specific means of serum lipids were estimated
with the t-test and differences between categories of life-
style and medication use with the Rao-Scott Chi-Square
test. The distribution of TG was skewed, therefore geo-
metric means were calculated. Kernel density distributions
of TC, HDL-C, and TG were plotted. Linear regression
analyses were performed with TC, HDL-C, and TG
(natural log-transformed) as dependent variables and
survey wave (GNHIES98, DEGS1) as independent vari-
able (Model 1). Model 2 was additionally adjusted for
age. As TC might be non-linearly associated with age,
with highest values at around 50 to 60 years [4], age
was included as a cubic spline with knots set at the
20th, 40th, 60th, and 80th percentile. Model 2 for TG
was additionally adjusted for fasting duration (“less
than four hours”, “four to eight hours”, “more than
eight hours”). Model 3 additionally included the follow-
ing covariables: educational status, smoking, coffee
consumption, processed foods consumption, whole-
grain bread consumption, high alcohol consumption,
sports activity, BMI category, lipid-lowering medica-
tion, and among women hormonal contraceptive use
and postmenopausal hormone therapy use. Correlation
coefficients between lifestyle variables were all lower
than 0.2 and variance inflation factors of all explanatory
variables were lower than 2.5. To improve the inter-
pretability of the results from regression analyses based
on natural log-transformed TG values, we calculated the
antilog of the regression coefficient.
All statistical analyses were performed using survey
procedures for complex samples in SAS 9.4 (SAS Insti-
tute, Cary, NC). Analyses were weighted using a weighting
factor to correct deviations from the population structure
in Germany with regard to age, sex, educational status,
federal state, and type of municipality as of 31.12.1997 for
GNHIES98 and 31.12.2010 for DEGS1 [26]. For the trend
analyses the GNHIES98 data were additionally age-
standardized for the population on 31 December 2010. P
values less than 0.05 were defined as statistically signifi-
cant based on two-sided tests.
In sensitivity analyses missing values were replaced by
the Fully Conditional Specification method using five
sets of imputation. For this purpose all analysis variables
and further auxiliary variables (weighting factor, sample
point, systolic blood pressure, and waist circumference)
were used. Data were imputed separately for both sexes
and for both study periods. Combined parameter esti-
mates, confidence intervals and P values were reported
and ranges of the model fit (min/max) were presented.
Results
Results for most study variables significantly changed be-
tween the two survey periods (Tables 1 and 2). Compared
to 1997–99 men and women were significantly better edu-
cated in 2008–11. In both sexes, coffee consumption,
processed foods consumption and sports activity in-
creased, while wholegrain bread consumption decreased.
The prevalence of current smokers and persons with high
alcohol consumption significantly decreased among men,
but not among women. In contrast, obesity significantly
increased among men, but not among women. The preva-
lence of persons using lipid-lowering medication more
than doubled between the two surveys in both sexes.
Among women, the prevalence of hormonal contraceptive
users significantly increased between survey periods, while
the prevalence of postmenopausal hormone therapy users
more than halved, between 1997–99 and 2008–11.
From 1997–99 to 2008–11 mean serum TC decreased
by 13 % among men and by 12 % among women (Tables 1
and 2). Geometric mean TG decreased by 14 % in men
and by 8 % in women. Mean HDL-C decreased by 5 %
among women only. In both sexes TC distributions were
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shifted to the left in 2008–11 compared to 1997–99
(Fig. 1). Distributions of HDL-C and TG did not shift, but
distributions were skewed and showed higher variability
in 1997–99 compared to 2008–11.
In linear regression models (Table 3) the age-adjusted
decline in mean TC was 0.83 mmol/l among men and
0.78 mmol/l among women. The age-adjusted decline in
mean HDL-C was 0.08 mmol/l in women. After adjust-
ing for age and fasting period the mean of TG declined
by 8 % in men and by 5 % in women. The decline in TC
between the surveys was only partly explained when
adjusting for age and additional covariables among men
(Model 3). Similarly, the decline in TG among men
between survey periods was reduced, even after adjust-
ment for age, fasting duration and additional covariables.
The decline in TC, TG, and HDL-C among women per-
sisted with adjustment for age and additional covariables.
In general, the results of the complete case analysis
are comparable to the multiple imputation analysis
(Additional file 2: Table S2), but a smaller part of the
difference between both survey periods among men
was explained using multiple imputed data.
Table 1 Study characteristics in 1997–99 and 2008–11 among men
GNHIES98a N = 3144 DEGS1b N = 3146 Pb
Age (mean, years) 44.3 (43.5–45.1) 46.5 (45.8–47.2) .600
Fasting duration (%) <4 h 28.5 (26.3–30.9) 10.6 (9.3–12.0) <.001
4 – 8 h 48.9 (46.8–51.0) 38.3 (36.3–40.5)
>8 h 22.6 (20.6–24.6) 51.1 (49.0–53.1)
Educational status (%) Low 48.2 (45.1–51.3) 35.0 (32.2–37.9) <.001
Middle 36.7 (34.3–39.2) 47.8 (45.3–50.3)
High 15.1 (13.4–17.0) 17.2 (15.4–19.2)
Lifestyle
Current smoking (%) No 61.8 (59.5–64.1) 67.7 (65.3–70.1) .009
Occasionally 6.0 (5.1–7.0) 6.4 (5.4–7.7)
Daily 32.2 (29.9–34.6) 25.8 (23.6–28.2)
Daily coffee consumption (%) 70.5 (68.3–72.6) 77.3 (75.3–79.2) <.001
Daily processed foods consumption (%) 65.4 (63.3–67.4) 68.6 (66.3–70.8) <.001
Wholegrain bread consumption (%) Never 13.8 (12.0–15.7) 16.7 (15.0–18.5) <.001
Less than daily 51.8 (49.8–53.9) 58.1 (55.9–60.3)
Daily 34.4 (32.0–36.7) 25.2 (23.1–27.3)
High alcohol consumption (%) 26.1 (24.0–28.4) 18.6 (16.9–20.3) <.001
Sports activity (%) No 44.9 (42.6–47.3) 32.2 (30.1–34.5) <.001
Up to 2 h per week 31.8 (30.1–33.6) 38.4 (36.1–40.8)
Regularly, at least 2 h per week 23.3 (21.4–25.2) 29.3 (27.4–31.4)
BMI category (%) Normal weight 32.1 (29.8–34.5) 32.7 (30.6–35.0) <.001
Overweight 48.6 (46.6–50.6) 43.7 (41.6–45.9)
Obese 19.3 (17.7–21.0) 23.5 (21.3–25.9)
Use of Medication
Lipid-lowering medication (%) 5.8 (4.9–7.0) 10.9 (9.7–12.3) <.001
Statins (%) 3.5 (2.8–4.3) 9.8 (8.5–11.1) <.001
Serum Lipids
Total cholesterol (mean, mmol/l) 5.97 (5.91–6.03) 5.19 (5.13–5.24) <.001
Triglycerides (geometric mean, mmol/l) 1.66 (1.61–1.71) 1.42 (1.38–1.45) <.001
High density lipoprotein (mean, mmol/l) 1.29 (1.27–1.31) 1.27 (1.25–1.29) .170
Differences between categorical variables were estimated with the Rao-Scott Chi-Square test and differences between mean serum lipid levels were estimated
with the t-test. P values < 0.05 were considered statistical significant (bold). Mean estimates are weighted: aStandardized to population structure as of 31st December
1997; bStandardized to population structure as of 31st December 2010
Number of missing values (GNHIES98/DEGS1): Fasting duration (120/23), educational status (87/24), current smoking (66/20), daily coffee consumption (81/69),
daily processed food consumption (78/59), wholegrain bread consumption (101/78), high alcohol consumption (79/61), sports activity (81/106), BMI category (15/20),
lipid-lowering medication/statins (12/11), total cholesterol (172/38), triglycerides (172/34), high density lipoprotein (174/34)
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The associations of TC, TG, and HDL with covariables
included in multiple linear regression models are pre-
sented in Additional file 3. Normal weight, non-smoking,
and no high alcohol consumption were independently re-
lated to lower TC among men, but not among women
(Additional file 3: Table S4). In both sexes, lower TC was
significantly and independently associated with the use of
lipid-lowering medication. Among women, lower TC was
significantly and independently associated with post-
menopausal hormone therapy use, while hormonal con-
traceptive use showed the opposite association. Lower
TG concentrations were independently related to non-
smoking, increased sports activity, normal weight, and
daily processed foods consumption in both sexes
(Additional file 3: Table S5). An independent and in-
verse relationship between coffee consumption and
Table 2 Study characteristics in 1997–99 and 2008–11 among women
GNHIES98a N = 3288 DEGS1b N = 3458 Pb
Age (mean, years) 46.2 (45.4–46.9) 47.5 (46.8–48.2) .870
Fasting duration (%) <4 h 27.6 (25.6–29.8) 8.5 (7.4–9.8) <.001
4–8 h 42.1 (40.0–44.2) 46.3 (44.3–48.4)
>8 h 30.3 (28.3–32.3) 45.2 (43.1–47.2)
Educational status (%) Low 50.5 (47.4–53.6) 36.2 (33.7–38.7) <.001
Middle 40.6 (38.2–43.0) 51.3 (48.9–53.6)
High 8.9 (7.6–10.5) 12.6 (10.8–14.6)
Lifestyle
Current smoking (%) No 70.9 (69.0–72.7) 72.8 (70.7–74.7) .790
Occasionally 6.0 (5.1–7.0) 5.8 (4.8–6.9)
Daily 23.2 (21.3–25.1) 21.5 (19.8–23.3)
Daily coffee consumption (%) 71.3 (69.1–73.5) 78.2 (76.4–79.9) <.001
Daily processed foods consumption (%) 52.4 (50.0–54.8) 62.3 (60.1–64.5) <.001
Wholegrain bread consumption (%) Never 7.3 (6.2–8.6) 8.9 (7.7–10.3) <.001
Less than daily 45.9 (43.4–48.5) 51.9 (49.4–54.4)
Daily 46.8 (44.3–49.2) 39.2 (36.7–41.8)
High alcohol consumption (%) 11.7 (10.2–13.5) 13.3 (12.0–14.7) .300
Sports activity (%) No 50.7 (48.1–53.3) 32.9 (30.8–35.1) <.001
Up to 2 h per week 34.0 (31.8–36.2) 45.2 (43.0–47.4)
Regularly, at least 2 h per week 15.4 (13.9–17.0) 21.9 (20.2–23.7)
BMI category (%) Normal weight 46.5 (44.2–48.9) 47.5 (45.3–49.7) .160
Overweight 30.6 (28.9–32.5) 29.2 (27.3–31.1)
Obese 23.2 (21.3–25.1) 23.4 (21.4–25.4)
Use of Medication
Lipid-lowering medication (%) 5.4 (4.5–6.4) 8.6 (7.5–9.8) <.001
Statins (%) 2.9 (2.2–3.7) 7.7 (6.7–8.7) <.001
Hormonal contraceptives (%) 16.8 (15.3–18.4) 21.2 (19.5–23.0) <.001
Postmenopausal hormone therapy (%) 11.7 (10.4–13.2) 5.0 (4.2–6.0) <.001
Serum Lipids
Total cholesterol (mean, mmol/l) 6.03 (5.98–6.08) 5.30 (5.24–5.37) <.001
Triglycerides (geometric mean, mmol/l) 1.20 (1.17–1.23) 1.10 (1.07–1.27) <.001
High density lipoprotein (mean, mmol/l) 1.66 (1.64–1.69) 1.58 (1.56–1.60) <.001
Differences between categorical variables were estimated with the Rao-Scott Chi-Square test and differences between mean serum lipid levels were estimated
with the t-test. P values < 0.05 were considered statistical significant (bold). Mean estimates are weighted: aStandardized to population structure as of 31st December
1997; bStandardized to population structure as of 31st December 2010
Number of missing values (GNHIES98/DEGS1): Fasting duration (151/9), educational status (107/24), current smoking (95/22), daily coffee consumption (106/55),
daily processed food consumption (99/47), wholegrain bread consumption (114/63), high alcohol consumption (102/48), sports activity (114/92), BMI category (37/30),
lipid-lowering medication/statins (13/13), hormonal contraceptives (13/13), postmenopausal hormone therapy (13/13), total cholesterol (196/40), triglycerides (196/36),
high density lipoprotein (196/37)
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serum TG was more pronounced among men while
higher intake of wholegrain bread was significantly re-
lated to lower TG in men only. The use of lipid-
lowering medication was related to higher serum TG
in men and women, as was hormonal contraceptive
use in women. Non-smoking, daily coffee consump-
tion, high alcohol consumption and normal weight
were independent determinants of higher HDL-C in
both sexes (Additional file 3: Table S6). An independent
and positive relationship between sports activity and
HDL-C was more pronounced in men, while higher
wholegrain bread intake and higher HDL-C correlated
among men only. Less than daily processed foods con-
sumption was associated with higher HDL-C values in
women only. Lipid-lowering medication use significantly
correlated with lower HDL-C among men. Among
women, hormonal contraceptive use was significantly
related to higher HDL-C.
Discussion
Between both German National Health Survey periods
1997–99 and 2008–11 TC (−13 and −12 %) and TG
levels (−14 and −8 %) decreased in men and women,
whereas HDL-C decreased in women only (−5 %). How-
ever, after adjustment for age and fasting duration almost
half of the decline in mean TG was explained among men
and women. Changes in lifestyle and use of medication
partly explained decreasing TC and TG among men, but
the survey effect remained significant even after consid-
eration of these covariables. Decreasing TC and HDL-C
levels among women remain unexplained.
The decline in serum TC observed in the present
study for Germany is comparable to findings from
northern Sweden, where mean TC levels decreased
from 6.38 mmol/l to 5.78 mmol/l (−9 %) in men and
from 6.32 mmol/l to 5.51 mmol/l (−13 %) in women
from 1986 to 2004 [11]. Similarly, TC levels decreased
Fig. 1 Change in serum lipid levels among men and women in 1997–99 and 2008–11. All figures are weighted population estimates: Standardized to
population structure as of 31st December 2010
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from 5.8 mmol/l to 5.3 mmol/l (−9 %) in men and from
5.6 mmol/l to 5.1 mmol/l (−9 %) among women in
Finland from 1992 to 2007 [13], with a 20 % decline ob-
served from 1982 to 2007. In the US the decline in TC
was lower. Between 1999–2002 and 2007–10 TC levels
declined from 5.23 mmol/l to 5.02 mmol/l (−4 %) among
men and from 5.28 mmol/l to 5.13 mmol/l (−3 %)
among women. Over the same time period, HDL-C in-
creased from 1.19 mmol/l to 1.22 mmol/l (3 %) among
men and from 1.46 mmol/l to 1.49 mmol/l among women
(2 %), and serum TG levels decreased from 1.49 mmol/l to
1.34 mmol/l (−10 %) among men and from 1.30 mmol/l to
1.15 mmol/l (−12 %) among women [10].
We found that the prevalence of persons using lipid-
lowering medication nearly doubled between 1997–99
and 2008–11 from 6 to 11 % among men and from 4 to
10 % among women. Not surprisingly, mainly statin use
increased. Statin prescription in Germany [27] as in
other European countries [28] dramatically increased,
ever since statins were recommended as first-line medi-
cation for patients with high low-density lipoprotein
cholesterol [29]. Comparable to our results the use of
lipid-lowering medication in north Sweden increased be-
tween 1994 and 2004 from almost 2 to 10 % among men
and women [11]. In Finland, lipid-lowering medication use
increased from 4 % in 1992 to 18 % in 2007, as compared
to 2 % in 1992 and 8 % in 2007 among women [13]. The
prevalence of US adults taking lipid-lowering medication
started from higher baseline levels with increases from 9 %
in 1999–2002 to 16 % in 2007–2010 [10]. In these previous
studies increased use of lipid-lowering medications ex-
plained about 0.1 mmol/l of the decline in TC levels
[11, 13, 30]. That leads us to assume that the change in
medication use had a similar impact in Germany.
We found an inverse association between use of lipid-
lowering medication and TG levels. Similarly, between
1996–97 and 2006–07 increasing TG levels were found
among French adults [12]. However, a previous review
on placebo-controlled randomized controlled trials and
uncontrolled before-and-after trials reported an inverse
association between the dose of atorvastatin and TG
levels [31]. Our unexpected finding might be due to life-
style differences between the group of users and non-
users of lipid-lowering medication. For instance, increased
TG levels are associated with changes in dietary habits
when saturated fats are replaced by carbohydrates [32].
In the present study, a number of lifestyle-related fac-
tors, known to affect serum lipids, significantly changed
over time and might have contributed to explain the ob-
served changes in serum lipids. Most consistently, sports
activity and coffee consumption increased over time. As
previously described [33, 34], we observed a significant
association between higher sports activity and lower
serum TG as well as higher HDL-C. However, these as-
sociations were more pronounced among men than
women in the present study. Thus, improved sports activity
may have contributed to decreases in TG. We found a posi-
tive association of daily coffee consumption with HDL-C
and an inverse association with TG. However, we had no
information on the coffee brewing method, which may have
Table 3 Linear regression models for serum lipids with survey wave (DEGS1 vs. GNHIES98) as independent variable
Men Women
Beta 95 % Confidence interval P R2 Beta 95 % Confidence interval P R2
Lower Upper Lower Upper
Total cholesterol (mmol/l)
Model 1 −0.845 −0.925 −0.765 <.001 .1087 −0.781 −0.861 −0.701 <.001 .0975
Model 2a −0.828 −0.904 −0.753 <.001 .2559 −0.782 −0.855 −0.708 <.001 .2977
Model 3b −0.779 −0.856 −0.702 <.001 .2833 −0.788 −0.865 −0.710 <.001 .3147
Triglycerides (log-transformed; mmol/l)
Model 1 −0.177 −0.210 −0.143 <.001 .0225 −0.098 −0.133 −0.062 <.001 .0090
Model 2a,c −0.088 −0.122 −0.054 <.001 .1298 −0.050 −0.084 −0.017 .004 .1584
Model 3b,c −0.081 −0.115 −0.047 <.001 .2315 −0.050 −0.084 −0.017 .003 .2817
High density lipoprotein cholesterol (mmol/l)
Model 1 −0.016 −0.040 0.007 .170 .0006 −0.081 −0.112 −0.051 <.001 .0094
Model 2a −0.016 −0.039 0.007 .170 .0089 −0.081 −0.111 −0.051 <.001 .0168
Model 3b −0.007 −0.031 0.017 .560 .1330 −0.099 −0.127 −0.071 <.001 .1571
Differences between mean serum lipid levels were estimated with the t test. P values < 0.05 were considered statistical significant (bold). All models are weighted
population estimates: standardized to population structure as of 31st December 2010
aAdjusted for age
bAdjusted for age, educational status, current smoking, coffee consumption, processed food consumption, wholegrain bread consumption, high alcohol
consumption, sports activity, body mass index category, use of lipid-lowering medication, hormonal contraceptives, and postmenopausal hormone therapy
cAdditionally adjusted for fasting duration
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some impact on the strength of the association [20]. In con-
trast to our findings, a previous meta-analysis of random-
ized controlled trials [20] showed increasing TC and TG
values among coffee drinkers, but no association with
HDL-C.
In the present study, significant reductions in tobacco
use and alcohol consumption as well as increases in
obesity over time were observed among men, while no
significant changes were evident among women. Daily
smoking decreased from 32 % in 1997–99 to 26 % in
2008–11 among men. This change most likely reflects
governmental actions, especially the tobacco tax increases
from 2002 to 2005, and the ban on smoking in public
places since 2007 [35]. However, in northern Sweden
where smoking prevalence decreased between 1994 and
2004 by 7 % (from 18 to 11 %) among men and by 8 %
(from 27 to 19 %) among women, the impact of smoking
on the population TC level was rather low [11]. As
expected based on previous evidence, we observed a
consistent and positive relationship between alcohol
consumption and HDL-C in both sexes [21].
Dietary fat quality and consumption of dietary fibre
have an impact on serum lipid levels [17], but due to
limited availability of food intake data we could only
consider consumption of wholegrain bread and con-
sumption of processed foods in our models. However,
these dietary variables did not consistently show the ex-
pected associations with serum lipids. Besides, the fre-
quency of wholegrain bread consumption decreased and
frequency of processed foods consumption increased
during the study period. In Finland changes in dietary
fat and cholesterol intake explained 0.7 mmol/l of the
serum cholesterol decline from 1982 to 2007 [13]. Due
to national prevention programmes which aimed to de-
crease CVD risk factors consumption of butter decreased,
while consumption of low-fat milk products, vegetables,
fruits, and berries increased [13]. Also in northern Sweden
the trend in TC is mainly due to favourable changes in
dietary habits from 1986 to 1999 [36]. In contrast, in the
US no significant changes in diet could be observed re-
garding intake of total fat, saturated fat, polyunsaturated
fat and dietary cholesterol from 1988–94 to 2007 [30].
The results of the German Nutrition Survey 1998 [37] and
the National Consumption study 2005–06 [38] suggest no
considerable change in total fat intake among men and
women. Furthermore, a regional study among children
found no substantial changes in fat quantity and quality
from 2000 to 2010 [39]. As previously reported, changes
in dietary habits among adults in Germany between
1997–99 to 2008–11 are characterized by increased fruit
consumption as well a decrease in the frequency of raw
and cooked vegetables consumption [40].
TFA seem to increase CVD risk and, among others, in-
crease serum TC levels and decrease HDL-C levels [41].
The main sources of TFA are commercially hydrogenated
oils, dairy fats and meats [42]. Due to societal pressure
food producers reduced TFA content in processed foods
during the last decade [42, 43]. The estimated mean intake
of TFA in Germany was 1.6 gram per day (0.7 % energy)
in 2013 [44]. Other studies suggested, that the changes
explain about 0.04 mmol/l [45] to 0.08 mmol/l [13] of the
TC decline. The decreasing TFA content could not be
considered from our data.
Hormonal contraceptive use, known to increase TC,
TG, and HDL-C [7], increased over time. Postmeno-
pausal hormone therapy use, known to decrease TC and
to increase HDL-C [8], substantially decreased in Germany
between the two survey periods as in many other countries
following the publication of the Women’s Health Initiative
[46]. The small decline of HDL-C among women was un-
expected, but a similar decline of HDL-C was also found
between 1990 to 1994 among both sexes in northern
Sweden (MONICA project), while HDL-C increased con-
sidering the period between 1986 and 1994 [47]. Among
women HDL-C values decreased from 1.56 mmol/l in
1990 to 1.51 mmol/l in 1994 on a similar level as observed
in this study. HDL-C increased among Non-Hispanic
white adults in the US between 1999–2002 and 2007–10
[10], but comparisons are difficult, since HDL-C is known
to be considerably lower in the US compared to the
German adult population even after adjustment for dif-
ferences in analytic methods and lifestyle variables in-
cluding alcohol consumption [48].
The major strength of the present study is the
population-based design which permits assessment of
changes in TC, HDL-C and TG among adults in
Germany over time at the national level. The observed
results are generalizable to the German resident adult
population, because analyses were based on large na-
tionwide samples of the resident population and survey
weights were applied accounting for the complex sam-
pling design and non-response. There are a number of
limitations. First, the model fit of the presented models
is rather low. This is not surprising since this popula-
tion wide sample is supposed to have a high biologic
and life style variability and important determinants of
lipid measures were not considered. Genetic factors
could not be considered, but would also not be ex-
pected to contribute essentially to explain changes over
time which was the major objective of the present ana-
lysis. Available information on food intake as well as
changes in food composition over the years (like lowering
of fat content in meat and changes in TFA in processed
foods) was incomplete, and more refined dietary data may
have contributed to the model fit and explain the change
in mean serum lipids over time probably much better.
Consideration of additional information that was avail-
able and comparable between the two survey periods
Truthmann et al. BMC Public Health  (2016) 16:240 Page 8 of 10
(e. g. diagnosed diabetes mellitus, hypertension, gly-
cated haemoglobin A1c) did not materially improve the
models and did not change the interpretation of the re-
sults (Additional file 2: Table S3). Secondly, LDL-C was
measured directly only in the more recent survey
(DEGS1, 2008–11). Calculation of LDL-C using the
Friedewald equation would have been possible, but not
valid at serum triglyceride concentrations ≥4.5 mmol/l.
We hence believe that inclusion of calculated LDL-C
would not strengthen our analysis which focused on
changes in lipid measurement distribution over time.
Third, changes in the analytic system, albeit not in the
serum lipid measurement method occurred between
the two surveys. Calibration based on parallel measure-
ment was not feasible, since the measurement device
from GNHIES98 (MEGA, Merck, Germany) was no
longer available. However, previous studies have shown
that even results obtained with different measurement
principles are highly correlated with differences in the
range of about 0.1 mmol/l [49]. Finally, guidelines rec-
ommend measuring TG at a fasting state [1, 29]. How-
ever, blood sampling in both German national health
surveys could not be generally conducted in a fasting
state, as survey visits had to be offered over the entire
day. Hours since last food intake were recorded in both
surveys and thus we were able to adjust linear regres-
sion models of TG for fasting duration.
Conclusions
Mean serum TC and TG declined considerably among
adults in Germany between the 1997–99 and 2008–11
national health interview and examination surveys. The
decline over time was more pronounced among men
than among women, and was partly explained by in-
creased use of lipid-lowering medication and improved
lifestyle among men only. HDL-C persisted in men and
slightly declined among women, which was not ex-
plained by changes in lifestyle or decrease in postmeno-
pausal hormone therapy. The influence of diet on the
trend of serum lipid levels could not be sufficiently taken
into account in this study. A small impact of the change
of the analytic system cannot be ruled out. Changes over
time may also differ by subgroups of the population
which needs further investigation.
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